ADVERTISEMENT
ADVERTISEMENT

Dendritic Cell Melanoma Vaccine

For this article, Eugene Russo interviewed Frank O. Nestle, a researcher in the department of dermatology at the University of Zurich Hospital. Data from the Web of Science (ISI, Philadelphia) show that this paper has been cited significantly more often than the average paper of the same type and age. F.O. Nestle, S. Alijagic, M. Gilliet, Y.S. Sun, S. Grabbe, R. Dummer, G. Burg, D. Schadendorf, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," Nature Medic

Eugene Russo

For this article, Eugene Russo interviewed Frank O. Nestle, a researcher in the department of dermatology at the University of Zurich Hospital. Data from the Web of Science (ISI, Philadelphia) show that this paper has been cited significantly more often than the average paper of the same type and age.

F.O. Nestle, S. Alijagic, M. Gilliet, Y.S. Sun, S. Grabbe, R. Dummer, G. Burg, D. Schadendorf, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," Nature Medicine, 4:328-32, March 1998. (Cited in more than 220 papers since publication)

Known to be an immunogenic cancer, melanoma has been increasingly targeted with a variety of immunotherapies in the past few years. Scientists know that some tumor-specific cytotoxic T cells recognize certain antigens on melanoma tumors, making a properly crafted and triggered immune response a potentially excellent way to rid the body of the disease. This paper reported the...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT